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Activation of peroxisome proliferator-activated receptor (PPAR) α, δ,a n dγ subtypes increases expression of genes involved in
fatty acid transport and oxidation and alters adiposity in animal models of obesity and type-2 diabetes. PPARpan agonists which
activate all three receptor subtypes have antidiabetic activity in animal models without the weight gain associated with selective
PPARγ agonists. Herein we report the eﬀects of selective PPAR agonists (GW9578, a PPARα agonist, GW0742, a PPARδ agonist,
GW7845, a PPARγ agonist), combination of PPARα and δ agonists, and PPARpan (PPARα/γ/δ) activators (GW4148 or GW9135)
on body weight (BW), body composition, food consumption, fatty acid oxidation, and serum chemistry of diet-induced obese
AKR/J mice. PPARα or PPARδ agonist treatment induced a slight decrease in fat mass (FM) while a PPARγ agonist increased BW
andFMcommensuratewithincreasedfoodconsumption.ThereductioninBWandfoodintakeaftercotreatmentwithPPARαand
δ agonists appeared to be synergistic. GW4148, a PPARpan agonist, induced a signiﬁcant and sustained reduction in BW and FM
similar to an eﬃcacious dose of rimonabant, an antiobesity compound. GW9135, a PPARpan agonist with weak activity at PPARδ,
induced weight loss initially followed by rebound weight gain reaching vehicle control levels by the end of the experiment. We
conclude that PPARα and PPARδ activations are critical to eﬀective weight loss induction. These results suggest that the PPARpan
compounds may be expected to maintain the beneﬁcial insulin sensitization eﬀects of a PPARγ agonist while either maintaining
weight or producing weight loss.
Copyright © 2007 W. Wallace Harrington et al. Thisis an open access article distributedunder theCreative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Obesity has risen to epidemic proportions world wide and
is one the most visible, yet often neglected,of public health
issues. It is now prevalent in virtually all age and socio-
economic groups in both developed and developing nations
[1]. Obesity is a complex, multifactorial condition produced
by genetic, social, and psychological factors,the most signiﬁ-
cant being high-fat diet and sedentary life style. The health
consequences of obesity range from increased risk of pre-
mature death to serious chronic conditions such as type 2
diabetes, dyslipidemia, atherosclerosis, hypertension, cardio-
vascular diseases, stroke, and certain forms of cancer [2–5].
Agents that reduce obesity through reductions in food intake
or increased energy expenditure could serve as therapeutic
options for the prevention of obesity and its comorbidities
[6–8].
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors that belong to the su-
perfamily of nuclear receptors [9]. Three subtypes, des-
ignated PPARα (NR1C1), PPARδ (NR1C2), and PPARγ
(NR1C3) have been identiﬁed whose endogenous ligands in-
clude fatty acids and fatty acid metabolites. PPARs form het-
erodimers with retinoid X receptors (RXRs) and bind to the
hexanucleotidic PPAR responsive element (PPRE), thereby
regulatingtheexpressionoftargetgenesinvolvedinlipidand
carbohydrate metabolism.
PPARs are found in species ranging from Xenopus to hu-
mans [9] with each receptor having a distinct tissue expres-
sion proﬁle. PPARα is expressed mainly in the liver, heart,
and muscle. The discovery that ﬁbrates are hypolipidemic
agents which activate PPARα suggested that this receptor
mayplayaroleinlipidmetabolism[9,10].Indeed,activation
of PPARα has been shown to upregulate genes involved in2 PPAR Research
hepatic lipid and lipoprotein metabolism and fatty acid oxi-
dation in skeletal muscle. In addition, these agents decrease
adiposity in animal models of obesity and type-2 diabetes
mellitus (T2DM). For example, fenoﬁbrate has been shown
to reduce food intake, body weight, and adiposity in sev-
eral mouse models and obesity-prone rats [11, 12]. PPARδ
has a broad pattern of distribution and is expressed in many
tissues, including muscle and kidney [13]. Recent work has
suggested that PPARδ is involved in overall energy regula-
tion and fatty acid oxidation in the muscle. Activation of
PPARδ hasalsobeenshowntoincreasehigh-densitylipopro-
tein cholesterol (HDL-c) in diabetic db/db mice and obese
rhesusmonkeys[14]. Studies by Wang et al. [15] suggest that
overexpression of PPARδ in adipose tissue protects against
diet-induced obesity in mice and treatment with a PPARδ
selective agonist reduces weight gain without eﬀects on food
intake in fat-fed mice [16].
ThediscoverythatglitazonesactivatePPARγ receptorhas
elucidatedtheroleofthisreceptorinlipidtransportandstor-
age and carbohydrate metabolism [17]. PPARγ is expressed
predominantly in white and brown adipose tissue and is im-
portant in the regulation and control of adipocyte develop-
ment and function [18] .T r e a t m e n tw i t hP P A R γ agonists en-
hances the action of insulin and reduces serum glucose in
subjects with T2DM, however, substantial body weight gain
also occurs that is comprised of both fat mass and ﬂuid vol-
ume [19–22]
PPARpan agonists can activate all three PPAR receptor
subtypes and exert a variety of eﬀects on multiple tissues si-
multaneously. This class of compounds has been shown to
have antidiabetic eﬃcacy in several animal models of T2DM
[23]. These compounds also aﬀect lipoprotein composition
and reduce atherosclerotic plaque formation without the
weight gain associated with PPARγ agonists suggesting their
utility in treatment of metabolic syndrome [24, 25].
A number of studies have described the eﬀect of individ-
ual PPAR agonists in a variety of animal models or exper-
imental paradigms [14, 26–28]. This study provides a sys-
tematic four-week evaluation of potent and selective agonists
of the three PPAR isoforms, the combination of PPARα and
δ agonists and PPARpan agonists in a single chronic model
of diet-induced obesity. We report the eﬀects of these agents
on body weight, body composition, fatty acid oxidation, and
clinical chemistry in obesity-prone AKR/J mice.
2. METHODS
2.1. Invitropotencyandselectivity
2.1.1. AssessmentofPPARactivationusingGAL4
transienttransfectionassay
The functional potency of selected ligands was evaluated us-
ing a transient transfection assay in CV-1 cells. The ligand
binding domains for murine PPARα,P P A R δ,a n dP P A R γ
were fused to the yeasttranscription factor GAL4 DNA bind-
ing domain as a chimera. CV-1 cells were propagated and
transiently transfected with expression vectors for the re-
spective PPAR chimera as previously described [29, 30]. Test
compounds were compared to reference comparators that
give maximum responses in this assay. Compounds which
produced an activation of at 70% or greater, compared to a
positive control, were considered full agonists.
2.1.2. ExvivoquantiﬁcationofPPAR-induced
fattyacidoxidation
Fatty acid oxidation (FAO) was determined by 14C-labeled
CO2 capture from tissue homogenates using a method mod-
iﬁed from Dohm et al. [31]. Following treatment with either
vehicle or a PPAR agonist, livers from fed mice were sur-
gically removed and a section excised from the same lobe.
The tissue was immediately weighed, minced with scissors
and placed in tubes (Falcon #2063) on ice. Cold SET buﬀer
(250mM Sucrose, 1mM EDTA, 10mM Tris, pH 7.4) was
added at a ratio of 10mL SET:1 gram of tissue and the tissue
homogenized on ice for 15 sec using a hand-held homoge-
nizer (Polytron PT1200; Kinematica AG). The homogenates
remained on ice until assayed.
The labeled reaction buﬀer was prepared by ﬁrst dry-
ing 14C-oleicacid(0.5μCi/reaction;PerkinElmer#NEC-317)
under nitrogen. The dried fraction is re-suspended in unla-
beled oleic acid such that the ﬁnal concentration of oleic acid
in the reaction buﬀer was 0.2mM. BSA was added slowly
while mixing to a ﬁnal concentration of 0.5% and the mix-
ture was incubated at 37◦C for 15 minutes. The labeled cock-
tail was then added to the reaction buﬀer to give a produce
concentration of 100mM sucrose, 10mM Tris pH 7.4, 4mM
ATP, 0.05mM Coenzyme A, 0.1mM malic acid, 1mM mag-
nesium chloride, 80mM potassium chloride, 5mM potas-
sium phosphate, 0.2mM EDTA, and 2mM L-carnitine, as
described previously [32, 33].
O x i d a t i o nr e a c t i o n sw e r ep e r f o r m e di nt u b e s( F a l c o n
#352059) ﬁtted with a stopper top (KONTES Glass Co.,
#882310-0000), center well (KONTES # 882320-0000), and
ﬁlter (Socorex #322.02) soaked with 175μL of 1N NaOH.
100μL of homogenate was dispensed into each tube and the
reactions initiated by adding 400μLo fr e a c t i o nb u ﬀer. The
tubes were quickly capped and incubated with gentle shak-
ing for 60 minutes in a 37◦C water bath. After incubation,
the ﬁlters were removed, from the tubes, placed in 7mL of
scintillant,andcountedfor2minutes(PerkinElmerTri-Carb
3100TR). The oxidative activity of each compound was cal-
culated as nmole CO2 captured/gram tissue/hour and re-
ported as fold change relative to vehicle control.
2.2. Invivoanimalstudies
All procedures were performed in compliance with the An-
imal Welfare Act, USDA regulations and approved by the
GlaxoSmithKline Institutional Animal Care and Use Com-
mittee. Animals were housed at 72◦F and 50% relative hu-
midity with a 12-hour light and dark cycle.
2.2.1. Compounds
All compounds evaluated were synthesized by the Medicinal
Chemistry Department at GlaxoSmithKline, Inc., and wereW. Wallace Harrington et al. 3
determined to be >90% pure by HPLC and/or NMR analy-
sis [34]. Dosing solutions of GW7845, GW0742, GW9578,
GW4148, and GW9135 were prepared as a suspension in
a vehicle of 0.5% methylcellulose and 0.1% Tween 80 and
dosed at 10mL/kg. Doses of each PPAR ligand were chosen
from results of previous in-house eﬃcacy studies.
2.2.2. EffectofPPARagonistsonbodyweight,
bodymass,andfoodconsumption
The eﬀects of monotherapy with selective PPAR agonists,
combination therapy with PPARα and PPARδ,a n dt r e a t -
ment with PPARpan agonists were evaluated in four ex-
periments in diet-induced obese (DIO) AKR/J mouse. The
AKR/J mouse is a polyoma-susceptible strain originally uti-
lized to study accelerated tumor development [35]. This
strain becomes obese and hyperinsulemic when fed a high
fat diet [36–39]. Age-matched, male AKR/J mice were al-
lowed ad libitum access to Research Diet D12331 (Research
Diet, Brunswick, NJ) at the Jackson Laboratories (Bar Har-
bor, ME) beginning at 6 weeks of age. The diet has an energy
density of 5.56 kcal/g (58% kcal from fat; 26% kcal from car-
bohydrates, and 16% kcal from protein). The animals were
allowed to become obese, achieving BW >40 grams before
shipping to GlaxoSmithKline laboratory animal facility at
13 weeks of age. The mice were housed 4 per cage in stan-
dard shoebox cages and were fed the high fat diet until they
reached approximately 50 grams. Age-matched lean control
animals obtained from Jackson Laboratories were fed a diet
of normal chow (3.04 kcal/g energy density, 12% kcal from
fat, LabDiet 5001, St. Louis, MO) and used for comparison.
At the beginning of each study, the animals were weighed
and body composition obtained using an EchoMRI-100
quantitative magnetic resonance (qMR, EchoMRI, Houston,
TX) whole body composition analyzer [40, 41]. Mice were
sorted into groups (n =8–10/group) such that BW and body
mass (% lean and fat mass) were not signiﬁcantly diﬀerent
at the beginning of the study. 16 lean control mice on stan-
dard chow were used as reference. All mice were dosed orally
with vehicle (0.5% methylcellulose and 0.1% Tween 80, 10
mL/kg) for six days prior to the beginning of dosing for ac-
climation to handling and treatment before drug treatment
was initiated.
In each experiment, BW of each animal was measured
and recorded three times weekly throughout the treatment
period. Body mass was obtained weekly on days 0, 7, 13, 20,
and 27 of treatment. The eﬀects of selective PPARα, δ,a n dγ
agonists on food consumption were also assessed. Food con-
sumption is expressed as total energy consumed (kcal) over
a 24-period and as cumulative consumption over the course
of the experiment.
The fat content of Research Diets D12331 chow results
in pellets that crumbles making it diﬃcult to quantify food
consumption thus, Research Diets D12451 chow (4.7 kcal/g
(45% kcal from fat, 35% kcal from carbohydrates and 20%
kcalfromprotein))wasusedinstudieswherefoodconsump-
tion was determined as these pellets are more solid. The an-
imals were transitioned two weeks before compound dosing
from Research Diets D12331 chow to Research Diets D12451
chow.Previousexperiments(datanotpresented)haveshown
that animals fed this diet maintain the same BW and fatmass
level as observed at the time of transition.
On the ﬁnal day of each experiment, a terminal blood
sample (800–1000μL) was obtained via cardiac puncture
under isoﬂurane anesthesia. Whole blood was placed in a
Terumo Capiject blood collection tube (Terumo Medical
Corp., Elkton, Md, USA), allowed to sit at room tempera-
ture for 20 minutes then centrifuged to obtain serum. Serum
levels of glucose, triglycerides, glycerol, nonesteriﬁed fatty
acids, total cholesterol, the high-density lipoprotein choles-
terol,and β-hydroxybutyrate were determined in all mice us-
ing an Olympus AU640 clinical chemistry immuno-analyzer
(Olympus America Inc., Melville, NY, USA). In addition,
liver weights were obtained following the terminal blood
sample on the ﬁnal day of the study and samples were used
to determine liver fatty acid oxidation activity.
3. EXPERIMENTAL DESIGN
Experiment 1 was designed to study the eﬀects of a selective
PPARα agonist and PPARδ agonist as mono and combina-
tion therapy. 48 mice were sorted into 6 groups and blocked
such that initial BW and body composition were not diﬀer-
ent between groups. Three groups of animals (n = 8) were
dosed with Vehicle, the PPARα agonist (GW9578, 1mg/kg),
or the PPARδ agonist (GW0742, 30mg/kg) for 4 weeks. Two
additional groups of mice were dosed for the ﬁrst 14 days
with either a PPARα agonist or a PPARδ agonist alone. At
day 15, the PPARδ agonist was added to the treatment regi-
men of animals dosed with PPARα, and the PPARα agonist
wasaddedtothedosingmaterialofanimalspreviouslydosed
with PPARδ alone. The sixth group was dosed with both the
PPARα and PPARδ agonists for the entire 28-day period. BW
and food consumption were assessed 3 times per week and
body composition was measured weekly.
In Experiment 2, 32 mice were sorted into 4 groups (n =
8/group) and dosed with vehicle and a selective PPARγ ago-
nist (GW7845, 3mg/kg) for 28 days. Rimonabant (RIM, 10
or 30mg/kg, q.d.), a CB1 receptor antagonist, was used as a
positive control for weight loss. As in Experiment 1, BW and
food consumption were determined 3 times per week and
body composition was measured weekly.
In Experiment 3, three groups of mice (n = 9) were
dosed for 28 days with vehicle or GW4148 (3 or 10mg/kg),
a PPARpan agonist that potently activates all three receptor
subtypes. In Experiment 4, ﬁve groups of mice (n = 8) were
dosed for 28 days with vehicle or GW9135 (3 or 10mg/kg),
a PPARpan agonist that has a diﬀerent proﬁle of PPARα, δ,
and γ activation from GW4148.
4. DATA ANALYSIS
All data are expressed as mean ± standard error of the mean.
Weight loss experiments were analyzed using Analysis of Co-
variance (ANCOVA) with repeated measures followed by
Dunnett’s post hoc test. Comparison of serum chemistry4 PPAR Research
Table 1: Activation of murine PPAR receptors by PPAR agonists in cell-based transactivation assays. Compounds were assayed for agonist
activity using the PPAR-GAL4 transactivation assay using an SPAP reporter transiently transfected in CV-1 cells as described in [25]. Data
are mean ± SE of four or more independent experiments. The EC50 value was deﬁned as the concentration of test compound that produced
50 ±10% of the maximal reporter activity.
Murine receptor activation (nM)
mPPARα %Max mPPARδ %Max mPPARγ %Max
GW9578 8.1 95 2344.2 76 2818.4 96
GW0742 8810.5 55 28.2 73 10000.0 67
GW7845 10770.9 30 10000.0 12 1.2 247
GW4148 41.8 114 9.4 134 37.3 88
GW9135 13.4 240 676.2 99 96.8 160
values, food consumption and fat and lean mass changes be-
tween start and end of studies was analyzed by two-way anal-
ysis of variance with repeated measuresmodel (ANOVA) fol-
lowed by Dunnett’s post hoc test. Values were considered to
be signiﬁcant when a value of P<. 05 was achieved.
5. RESULTS
5.1. AssessmentofPPARactivationusingGAL4
transienttransfectionassay
Each compound evaluated in vivo was characterized with re-
gard to activation of the three PPAR subtypes [36] as shown
inTable 1.Thesecompoundsarefullagonistsoftheirrespec-
tive receptors. GW9578 is a potent agonist of murine PPARα
receptors with an EC50of 8 nM and more than a 250-fold se-
lectivity over PPARγ and PPARδ [34]. GW0742 is a potent
and selective PPARδ agonist, (EC50 = 28 nM) having a 300-
fold selectivity over PPARα and PPARγ [26]. GW7845 is a
potent and selective PPARγ agonist with an EC50 of 1.2 nM
and >1000-fold selectivity over the other murine PPAR sub-
types[27].BothPPARpanagonistsusedinthisstudyactivate
all of the PPAR subtypes, however, GW4148 and GW9135
have diﬀerent potency proﬁles. GW4148 is nearly equipotent
at murine PPARα/δ/γ (EC50 < 100 nM), while GW9135 is
most potent at the PPARα receptor with signiﬁcant activity
on PPARγ and weak potency at PPARδ.
5.2. Invivostudies
Experiment1.Effectofmono-andcombinationtherapyof
PPARαandPPARδ AgonistsinObeseAKR/JMice
The ﬁrst experiment was designed to compare the eﬀects of
selective PPARα (GW9578, 1mg/kg) and PPARδ (GW0742,
30mg/kg) agonists, and the combination of the two agents,
on BW, fat mass (FM), lean mass (LM), and food con-
sumption. Data are shown in Figure 1, Figure 2,a n dTable 2.
Vehicle-treated mice weighed approximately 50 grams at ini-
tiation of the study and BW did not change during the study.
While there was an initial weight loss trend, neither com-
pound induced a sustained decrease in BW after 28 days of
dosing (see Figure 1(a)).
On day 0, FM and LM (see Table 2)c o m p r i s e d2 1 .8 ±
1.6% (7.2±0.6gr a m s )a n d6 3 .1±1.3% (20.8±0.4gr a m s )o f
total body weight, respectively, in lean mice. The remaining
mass of each animal is composed of bone, free water (as cel-
lular,interstitialand,bloodvolumes),andthecontentsofthe
gastrointestinal tract and bladder. In the DIO vehicle group,
FM was nearly twice that of the lean mice (16.1 ± 1.4g r a m s ;
39.5% of BW), but LM was similar (21.2 ±0.2 grams; 53.1%
of BW). FM and LM did not change in the DIO or lean vehi-
cle groups in any of the experiments.
In spite of the fact that neither agent produced a signif-
icant decrease in BW, there was a slight decrease in FM af-
ter treatment with either the PPARα or PPARδ agonist while
LM was unaﬀected (see Table 2, Experiment 1). Both agents
produced a statistically signiﬁcant increase in liver weight
of nearly 1 gram that appears to have counterbalanced the
change in fat mass resulting in unaltered BW.
Both the PPARα and PPARδ agonists aﬀected food con-
sumption. Compared to vehicle-treated animals, the PPARα
agonist reduced food consumption while the PPARδ agonist
produced a small but statistically signiﬁcant increase in feed-
ing (see Figure 2(a)). The eﬀectofPPARα activation on feed-
ing did not occur until day 10, the same point when weight
loss had reached a plateau and subsequently began to re-
bound.
A second goal of Experiment 1 was to examine the ef-
fects of PPARα and PPARδ in combination on BW, body
mass,andfoodconsumption.MinimalBWchangeswereob-
served with the PPARα or PPARδ agonists alone similar to
Figure 1(a). At Day 14, the PPARα agonist was added to the
group dosed with PPARδ alone or vice versa for an addi-
tional 14 days. Both conditions resulted in weight loss (see
Figure 1(b)) greater than observed with either agent alone.
The overall weight loss from either combination was approx-
imately15%whichwascommensuratetothedecreaseinFM.
A third group of mice was dosed with a combination of the
PPARα and PPARδ agonists for the entire 28- day period.
This treatment resulted in a 22% reduction in BW that oc-
curred by 14 days. Both ﬁnal BW and FM were similar to
that of lean controls.
Addition of the PPARδ agonist to the PPARα agonist
dosing regimen at 14 days did not have a signiﬁcant eﬀect
on food consumption (see Figure 2(b)). However, adding
PPARα to the dosing regimen of mice receiving the PPARδ
agonist reduced food consumption to the level seen with
PPARα agonist alone. Interestingly, simultaneous dosingW. Wallace Harrington et al. 5
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Figure 1: Eﬀect of treatment with selective PPARα and PPARδ ag-
onists on BW in lean and DIO AKR/J mice. (a) GW9578, a PPARα
agonist (1mg/kg), GW0742, a PPARδ agonist (30mg/kg). (b) Filled
triangle: GW9578 dosed for 14 days then combined with GW0742;
ﬁlled diamond: GW0742 dosed for 14 days then combined with
GW9578; ﬁlled square: GW9578 and GW0742 dosed together for
28 days. The arrow indicates the point at which the sequential com-
bination of PPARα and PPARδ began. Data were analyzed by AN-
COVA with repeated measures followed by Dunnett’s post hoc test.
Values were considered to be signiﬁcant (∗) when a value of P<. 05
was achieved. N = 8–10 animals/group.
from study outset with both the PPARα and PPARδ agonists
reduced feeding to a greater extent then the sequential addi-
tion of the agents.
Experiment2.EffectofaPPARγ agonistand
rimonabantinobeseAKR/Jmice
WhereExperiment1focusedontheeﬀectsofselectivePPARα
and PPARδ agonists, Experiment 2 was designed to exam-
ine the eﬀect of GW7845, a selective PPARγ agonist dosed
at 3mg/kg on BW, FM, LM, and food consumption. RIM, a
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Figure 2: Eﬀect of treatment with selective PPARα and PPARδ ag-
onists on food consumption (kcal) in lean and DIO AKR/J mice.
(a) GW9578, a PPARα agonist (1mg/kg), GW0742, a PPARδ ag-
onist (30mg/kg). (b) Filled triangle: GW9578 dosed for 14 days
then combined with GW0742; ﬁlled diamond: GW0742 dosed for
14 days then combined with GW9578; ﬁlled square: GW9578 and
GW0742 dosed together for 28 days. The arrow indicates the point
at which the sequential combination of PPARα and PPARδ began.
Data were analyzed by ANCOVA with repeated measures followed
by Dunnett’s post hoc test. Values were considered to be signiﬁcant
(∗) when a value of P<. 05 was achieved. N = 8–10 animals/group.
CB-1R antagonist was used as a positive control for weight
loss.
Treatment with RIM at doses of 10 and 30mg/kg pro-
duced signiﬁcant, dose-related decreases of BW. At the high-
est dose, RIM reduced BW by 17% within the ﬁrst 10 days
of treatment (see Figure 3(a)) and the eﬀect was main-
tained over the remainder of the study. RIM also decreased
FM in a dose-dependent manner (see Table 2, Experiment
2). In contrast, the PPARγ agonist produced a steady and6 PPAR Research
Table 2: Eﬀect of treatment with PPAR agonists on body weight (BW), body composition (FM and LM), and liver weight (LW). Shown in
the table are body weight (g) and fat and lean mass (g) values of each group. FM and LM were determined using qMR at the ﬁnal day of
the study (day 28). LW was obtained from terminal collection at the end of the experiment. N = 8 mice/group. Data are expressed as mean
+/− SEM. Doses are in mg/kg. Data were analyzed by two-way ANOVA with repeated measures followed by post hoc t-test. Data achieved
signiﬁcance when P<. 05(∗).
Treatment BW day 0
(grams)
BW day 28
(grams)
Fat mass
day 28
(grams)
Lean mass
day 28
(grams)
Liver weight
(grams)
Experiment 1 Lean vehicle 36.6 ±0.83 7 .0 ±1.08 .4 ±1.12 3 .2 ±0.41 .8 ±0.1
DIO vehicle 50.4 ±1.35 2 .1 ±1.82 0 .8 ±1.32 9 .3 ±0.72 .0 ±0.2
GW9578 (1) 52.1 ±1.15 1 .3 ±1.61 8 .4 ±0.93 0 .9 ±0.82 .6 ±0.1 ∗
GW0742 (30) 51.6 ±1.15 0 .2 ±1.21 8 .4 ±0.7 ∗ 29.7 ±0.73 .2 ±0.1 ∗
GW9578 +
GW4148
(after week 2)
49.0 ±0.64 1 .3 ±1.2 ∗ 10.2 ±0.9 ∗ 29.1 ±0.54 .3 ±0.2 ∗
GW4148 +
GW9578
(after week 2)
49.5 ±1.04 2 .7 ±0.8 ∗ 11.0 ±0.8 ∗ 29.5 ±0.94 .3 ±0.1 ∗
GW9578 and
GW4148
4w e e k s
50.5 ±0.93 9 .3 ±0.9 ∗ 9.1 ±0.4 ∗ 28.4 ±0.74 .9 ±0.1 ∗
Experiment 2 DIO vehicle 50.8 ±0.44 9 .2 ±0.52 0 .7 ±0.82 5 .4 ±1.01 .9 ±0.1
RIM (10) 50.6 ±0.84 4 .1 ±1.3 ∗ 15.0 ±0.92 5 .2 ±0.82 .0 ±0.1
RIM (30) 51.0 ±0.74 1 .8 ±0.5 ∗ 11.6 ±0.32 6 .5 ±0.52 .0 ±0.1
GW7845 (3) 50.9 ±1.25 4 .6 ±1.7 ∗ 23.5 ±1.32 8 .7 ±0.62 .0 ±0.1
Experiment 3 DIO vehicle 40.8 ±1.34 4 .9 ±1.61 7 .6 ±1.62 3 .5 ±0.51 .9 ±0.1
GW4148 (3) 40.8 ±1.24 2 .0 ±0.91 3 .5 ±0.9 ∗ 23.7 ±0.32 .9 ±0.1 ∗
GW4148 (10) 40.7 ±1.53 6 .6 ±0.9 ∗ 10.3 ±0.6 ∗ 22.3 ±0.53 .4 ±0.1 ∗
Experiment 4 Lean vehicle 33.7 ±0.73 4 .4 ±0.88 .4 ±0.82 2 .0 ±0.61 .7 ±0.1
DIO vehicle 40.6 ±1.94 3 .1 ±1.61 6 .5 ±1.12 3 .4 ±0.61 .9 ±0.1
GW9135 (3) 41.1 ±1.84 2 .5 ±1.91 4 .9 ±1.52 4 .1 ±0.33 .0 ±0.2 ∗
GW9135 (10) 41.2 ±1.54 0 .3 ±1.21 2 .3 ±0.8 ∗ 23.0 ±0.43 .3 ±0.1 ∗
consistent increase in BW over the course of the experiment
(see Figure 3(b)). After 28 days, the weight of these animals
had increased by almost 4 grams (8.6 ± 1.4% BW) and the
mice were continuing to gain weight at 4 weeks. The PPARγ
agonist produced a signiﬁcant increase in FM over the 28
days of the study accounting for much of the weight gain in
these animals.
RIM induced dose-related decreases in food consump-
tion with the greatest suppression observed on day 3 (see
Figure 4(a)). After day 3, food consumption suppression be-
gan to wane, eventually returning to control levels by day 10
and remained at that level for the duration of the study. In
contrast to the eﬀect of RIM, food consumption of animals
dosed with the PPARγ agonist increased 46% after only one
day and remained elevated by more than 20% over the re-
maining treatment period (see Figure 4(b)).
Experiments3and4.EffectofPPARpanagonists
inobeseAKR/Jmice
Experiments3and4exploretheeﬀectsoftwoPPARpanago-
nists with diﬀerent selectivity proﬁles (see Figure 5, Table 1).
GW4148, a potent activator of all three PPAR receptor sub-
types, was used in Experiment 3. Dosed at 3mg/kg, GW4148
did not induce weight loss. In contrast, a dose of 10mg/kg
signiﬁcantly decreased BW by 18% after 19 days of dosing
(seeFigure 5(a)). This changemirrored the eﬀectsseen when
PPARα and PPARδ were coadministered in Experiment 1.
GW4148 also produced a signiﬁcant decrease in FM that was
commensurate with the reduction in BW.
GW9135 is a PPARpan compound with a diﬀerent pat-
tern of activation than GW9148, being very potent at PPARα
and PPARγ and weaker at PPARδ. Dosing GW9135 at
3mg/kghadnoeﬀect on BW (see Figure 5(b)). Treatment
with 10mg/kg GW9135 reduced body weight 10% by day
8, however, the mice regained weight after that time and ﬁ-
nal BW was not signiﬁcantly diﬀerent from vehicle-treated
animals at day 27 (see Figure 5(b)). This dose of GW9135
signiﬁcantly reduced FM by 4 grams. Both GW4148 and
GW9135treatmentsincreasedliverweightsbyapproximately
2.5 grams (see Table 2) which counterbalanced the ﬁnal BW
to some extent.
EffectofPPARagonistsonserumchemistry
Serum chemistry results are shown as group means in
Table 3. None of the PPAR agonists tested in these experi-
ments had a signiﬁcant eﬀect on blood glucose levels. TheW. Wallace Harrington et al. 7
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Figure 3: Eﬀect of treatment with rimonabant or selective PPARγ
agonist on BW. (a) RIM (10 and 30mg/kg). (b) GW7845, a selective
PPARγ agonist (3mg/kg). Data were analyzed by ANCOVA with re-
peated measures followed by Dunnett’s post hoc test. Values were
considered to be signiﬁcant (∗) when the value of P<. 05 was
achieved. N = 8–10 animals/group.
PPARα and PPARδ agonists alone signiﬁcantly reduced cir-
culating insulin (INS) levels. The combination of the two
agentsnotonlyreducedinsulinbutalsosigniﬁcantlyreduced
triglyceride (TG) and nonesteriﬁed fatty acids (NEFAs) and
elevated total cholesterol (CHOL), high-density lipoprotein
cholesterol (HDL-c), and β-Hydroxybutyric acid (βHBA).
The selective PPARγ agonist produced a signiﬁcant reduc-
tion in circulating INS, TG, and NEFA levels. Both PPARpan
agonists signiﬁcantly reduced fed glucose, INS, NEFAs, and
TG and increased total CHOL, HDL-c, and βHBA.
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Figure 4: Eﬀect of treatment with rimonabant or selective PPARγ
agonist on food consumption (kcal). (a) RIM (10 and 30mg/kg).
(b) GW7845, a selective PPARγ agonist (3mg/kg). Data were ana-
lyzed by ANCOVA with repeated measures followed by Dunnett’s
post hoc test. Values were considered to be signiﬁcant (∗) when the
value of P<. 05 was achieved. N = 8–10 animals/group.
EffectofPPARagonistsonexvivofattyacidoxidation
Changes in drug-induced fatty acid oxidation (FAO) were
evaluated in mouse liver extracts from animals treated with
compound for 28 days (see Figure 6). Activation of the
PPARδ agonistproduceda1.9-foldincreaseinFAOwhilethe
PPARγ agonist and PPARα agonist were not diﬀerent from
vehicle. The PPARpan agonists elicited responses similar to
the PPARδ agonist and this response most likely reﬂects the
activity of PPARpan agonists at the PPARδ receptor.8 PPAR Research
Table 3: Group means of clinical chemistry results of DIO-AKRmice. Terminal blood samples were obtained at the end of treatment. Serum
levels of analytes were determined using an Olympus AU640 clinical chemistry analyzer and analyzed by a two-way analysis of variance with
repeated measures model (ANOVA) followed by Dunnett’s post hoc test. Values were considered to be signiﬁcant (∗) when the value of
P<. 05 was achieved.
Treatment Glucose
(mg/dL)
Insulin
(ng/mL)
Triglyceride
(mg/dL)
NEFA
(mEq/L)
Cholesterol
(mg/dL)
HDL-C
(mg/dL)
bHBA
(mg/dL)
Experiment 1 Lean vehicle 211.3 ±7.81 .7 ±1.4 194.7 ±0.70 .7 ±0.03 89.5 ±1.65 7 .2 ±1.12 .1 ±0.2
DIO vehicle 241.2 ±7.41 1 .2 ±2.1 154.5 ±8.10 .8 ±0.02 188.7 ±12.5 131.8 ±4.52 .0 ±0.2
GW9578 (1) 248.0 ±16.63 .1 ±1.6 ∗ 168.3 ±15.40 .9 ±0.04 117.1 ±4.18 6 .6 ±2.73 .2 ±1.1
GW0742 (30) 253.3 ±8.92 .2 ±1.2 ∗ 174.9 ±10.30 .9 ±0.02 171.9 ±2.9 118.4 ±1.63 .8 ±0.3 ∗
GW9578 +
GW0742 after
week 2
211.5 ±14.21 .9 ±0.9 ∗ 97.5 ±5.8 ∗ 0.6 ±0.02 ∗ 207.5 ±4.5 ∗ 131.8 ±4.57 .0 ±0.5 ∗
GW4148 +
GW0742 after
week 2
157.4 ±2.4 ∗ 2.9 ±1.1 ∗ 100.0 ±8.9 ∗ 0.6 ±0.04 ∗ 210.1 ±8.5 ∗ 132.5 ±4.77 .0 ±1.4 ∗
GW9578 and
GW0742
4w e e k s
199.1 ±1.6 ∗ 2.6 ±0.8 ∗ 128.1 ±9.0 ∗ 0.8 ±0.04 234.4 ±5.5 ∗ 141.8 ±2.36 .9 ±0.8 ∗
Experiment 2 DIO vehicle 225.4 ±11.71 0 .2 ±0.5 152.3 ±0.80 .7 ±0.8 114.9 ±2.98 1 .8 ±1.61 .6 ±0.2
RIM (10) 230.1 ±16.67 .2 ±2.5 ∗ 181.4 ±36.10 .8 ±0.05 147.3 ±9.1 ∗ 95.1 ±4.6 ∗ 2.5 ±0.2 ∗
RIM (30) 215.3 ±13.03 .4 ±0.7 ∗ 159.7 ±16.10 .9 ±0.02 143.4 ±4.0 ∗ 116.9 ±2.6 ∗ 1.8 ±0.2
GW7845 (3) 222.3 ±9.42 .1 ±0.4 ∗ 112.3 ±5.7 ∗ 0.6 ±0.03 ∗ 106.1 ±4.26 5 .0 ±0.9 ∗ 1.5 ±0.1
Experiment 3 DIO vehicle 234.0 ±9.46 .7 ±1.9 163.5 ±16.20 .8 ±0.07 116.1 ±5.99 1 .1 ±3.72 .9 ±0.2
GW4148 (3) 233.3 ±14.61 .8 ±0.3 ∗ 62.6 ±4.1 ∗ 0.5 ±0.03 ∗ 178.9 ±3.7 ∗ 52.9 ±0.1 ∗ 5.1 ±0.9 ∗
GW4148 (10) 214.0±10.9 ∗ 1.3 ±0.3 ∗ 48.4 ±3.6 ∗ 0.5 ±0.04 ∗ 192.6 ±6.8 ∗ 131.1 ±3.6 ∗ 6.5 ±1.1 ∗
Experiment 4 Lean vehicle 189.5 ±8.61 .2 ±0.2 220.5 ±14.00 .7 ±0.04 70.0 ±1.95 1 .7 ±1.41 .6 ±0.1
DIO Vehicle 196.0 ±11.11 1 .2 ±2.1 277.6 ±25.21 .5 ±0.10 122.8 ±4.7 106.0 ±2.83 .7 ±0.6
GW9135 (3) 215.0 ±14.12 .9 ±0.5 ∗ 113.8 ±9.9 ∗ 0.8 ±0.04 ∗ 188.9 ±4.9 ∗ 149.4 ±2.4 ∗ 4.4 ±0.6 ∗
GW9135 (10) 196.1 ±5.61 .4 ±0.4 ∗ 58.8 ±2.4 ∗ 0.6 ±0.02 ∗ 183.8 ±5.2 ∗ 141.9 ±2.8 ∗ 4.3 ±0.4 ∗
6. DISCUSSION
There is a critical medical need to develop eﬀective strategies
for long-term weight loss and weight maintenance although
it is unlikely that any single therapy will yield maximal eﬃ-
cacy. Currently, the few therapies actually shown to be eﬀec-
tive for weight loss include lifestyle modiﬁcations (diet and
exercise), bariatric surgery, and pharmacological targets that
modulate central pathways that regulate food intake [41].
PPARs are known to modulate enzymes involved in lipid
metabolism and are expressed in many, if not all, metaboli-
callyactivetissuesincludingliver,heart,kidney,skeletalmus-
cle, intestine, pancreas, and adipose tissue [42, 43]. This sug-
gests that PPARs play a key role in energy metabolism and
homeostasisthatmayultimatelyaﬀectbodyweightandbody
mass. In this report, we present data showing that potent and
selective agonists of all three PPAR isoforms serve to modu-
late food intake and energy balance in DIO AKR/J mice.
Selective activators of PPARγ, such as glitazones, have
been successfully used to treat T2DM for nearly a decade.
Treatment with rosiglitazone and pioglitazone induce body
weight gain in mice [45, 46, 49], rats [44, 47–50], nonhuman
primates [51, 52], and humans [53–55]. Weight gain is man-
ifested as increased adiposity, total body water and plasma
volume. In this report, mice treated with a potent and se-
lective PPARγ activator gained more weight than obese ve-
hicle controls and the weight gain could be completely ac-
counted for by increased fat mass which was equivalent to
the increase in caloric intake. In addition to stimulation of
food consumption, activation of PPARγ promotes triglyc-
eride accumulation by increasing expression of genes modu-
lating adipogenesis [56–58], lipid transport [58, 59], storage
[46,60],andglucosehomeostasis[61].Wealsoobservedthat
GW7845 had no eﬀect on FAO in mouse liver. In summary,
PPARγ agonism induces food consumption and energy stor-
age without an eﬀect on energy utilization resulting in net
weight gain.
A number of studies have suggested that PPARδ ago-
nists regulate food intake, body weight, insulin sensitivity,
and adiposity [8, 62–68]. Transgenic mice in which consti-
tutively active PPARδ is expressed in muscle are highly resis-
tant to high-fat, diet-induced obesity [15]. Administration
of GW501516, a selective PPARδ agonist, promotes FAO and
utilization,depletinglipidaccumulationinadipocytes,skele-
tal muscle, and liver in DIO, ob/ob [68], and db/db mice
[67].
Similarly, there are numerous studies that suggest that
PPARα can regulate food intake, body weight, and adiposityW. Wallace Harrington et al. 9
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Figure 5: Eﬀect of treatment with PPARpan agonists on BW. (a)
GW4148 dosed at 3 and 10mg/kg. (b) GW9135 dosed at 3 and
10mg/kg. Data are expressed as mean ± SEM and were analyzed by
ANCOVA with repeated measures followed by Dunnett’s post hoc
test. Values were considered to be signiﬁcant (∗) when the value of
P<. 05 was achieved. N = 8 animals/group.
in rodents [69–74]. PPARα has been shown to modulate tar-
get genes involved in uptake, activation, and degradation of
fatty acids maintaining lipid homeostasis in liver, heart, and
oxidative muscles [33, 75, 76]. It is possible that the combi-
nationofthesemechanismscouldresultinreductionofbody
weight. Djouadi et al. [76] and Muoio et al. [33] have shown
that the body weight of PPARα-KO mice was greater than
WT littermates, and that they became obese when fed a high
fat diet, conﬁrming the role of PPARα receptors in modulat-
ing energy utilization and BW in rodents. In humans, ﬁbrate
treatmenthasnotbeenassociatedwithbodyweightloss(73),
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Figure 6: Eﬀect of PPAR agonist treatment on fatty acid oxidation
(FAO) in liver was assessed using a 14C capture method modiﬁed
from Dohm et al. [28]. Data are expressed as fold change from ve-
hicle control (mean ± SEM). N = 6 determinations/compound.
thus, the role of PPARα agonism in human body weight reg-
ulation is unclear.
NeitherPPARαnorPPARδ agonistshadasustainedeﬀect
on body weight. While the increase in liver weights observed
with both treatments counterbalanced the initial weight loss
inducedbythesecompounds,thischangedidnotcompletely
explain the rebound.
GW0742, the PPARδ agonist, had a transient stimulatory
eﬀect on food intake from days 12–17 and it was during this
timethatthereboundincreaseinweightoccurred.Therewas
a signiﬁcant increase in liver FAO induced by GW0742 af-
ter chronic dosing. The increase in food intake may have oc-
curred in response to elevated energy expenditure, thus, an
agentthatonlymodulatesenergyexpendituredidnotinduce
signiﬁcant weight loss in this model.
After 10 days of treatment with GW9578, the PPARα ag-
onist, a signiﬁcant suppression of food intake was observed
that persisted throughout the rest of the study. The timing
of this eﬀect coincided with the timing of the rebound in
weight gain. Currently, we do not have an explanation for
this phenomenon, yet it appears that chronic PPARα ago-
nism induces a metabolic compensation resulting in weight
regain and the food intake suppression could be a counter-
acting mechanism. The eﬀect on food consumption could
be regulated centrally as PPARα is expressed in low but de-
tectable levels in mouse hypothalamus, a major center of ap-
petite and satiety regulation. PPARα could also modulate pe-
ripheral mechanisms that aﬀect appetite or central response
to lipid levels resulting from changes in FAO [12, 75]. While
several reports have shown that PPARα increased FAO, the
measurement of this parameter at the end of the study indi-
cated that there was only a modest alteration. We did observe
weight loss during the ﬁrst 10 days of the study without a
change in food intake thus it is possible that there could have
been induction of FAO during this time.10 PPAR Research
A combination study of PPARα and PPARδ agonists
was performed to determine if greater weight loss could be
achieved together than with either compound alone. After
2 weeks of dosing with either single agent, addition of the
second agent further reduced body weight and fat mass, sug-
gesting a synergistic eﬀect of the two agents. Combination
dosing of both agents for the entire 4 weeks of the study pro-
duced even greater reduction in body weight and fat mass.
Interestingly, the suppression of food intake after addition
of GW9578 to GW0742 and with the straight combination
dosing occurred immediately as opposed to the 10-day delay
observed with GW9578 alone. The immediate eﬀect on food
intake through PPARα, increase in liver FAO from PPARδ,
and the initial induction of weight loss by PPARα through
a nonfood intake mechanism all account for the greater ef-
ﬁcacy observed with the combination dosing from day 1 of
treatment.
PPARpan agonists are a class of compounds that acti-
vateallthreePPARreceptorsubtypes andarecurrentlybeing
evaluatedasantidiabeticagents.ComparedtoselectivePPAR
agonists, PPARpan ligands are expected to display unique
characteristics as a result of ligand-activation proﬁles com-
bining features of all three PPAR receptor subtypes, how-
ever, the eﬀects are not simply the sum of the activities, but
reﬂect a careful balance of lipid handling and energy. Both
compounds used in this study are potent activators of all
three isoforms but the potency ratio across the isoforms is
diﬀerent. GW4148 is an extremely potent agonist of murine
PPARδ (9 nM) and is 4-fold selective over PPARα or PPARγ
receptors. In contrast, GW9135 is a potent agonist of murine
PPARα (13nM) and is 18-fold and 50-fold selective over
PPARγ and PPARδ, respectively. Other factors such as cofac-
tor aﬃnities contribute to the physiological behavior of each
molecule.
GW9135 had little eﬀect on overall weight loss, a pattern
not diﬀerent from PPARα agonist treatment alone, where
there was an initial decrease in weight followed by regain.
This eﬀect can be explained by the greater potency of the
molecule at PPARα and its weaker potency on PPARδ .I n
contrast, GW4148, which is most potent at the PPARα and
PPARδ receptors, behaved similarly to combination dosing
of GW9578 and GW0742 producing signiﬁcant weight loss
at 10/mg/kg.
Contrary to the diﬀerential eﬀects on body weight, both
PPARpan agonists produced similar metabolic eﬀects. Each
compound reduced TG, NEFA, and circulating insulin lev-
els, and elevated HDL-c and bHBA. A similar pattern was
noted with the combination of GW9578 and GW0742, how-
ever, these two agents alone did not have signiﬁcant eﬀects
on any parameter except insulin. The combination of PPARα
and PPARδ activation results in a synergistic eﬀect on serum
chemistry parameters.
In summary, these studies demonstrate that PPARs are
integrally involved in energy maintenance. The PPARα and
PPARδ receptors are responsible for induction of weight loss
in AKR/J mice through suppression of food intake and in-
creasedenergyexpenditure.ActivationofPPARαandPPARδ
receptors by PPARpan compounds may be expected to in-
duce weight loss or provide weight maintenance while com-
bining the beneﬁcial insulin sensitization eﬀects of a PPARγ
agonist.
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PPAR: Peroxisome proliferator-activated receptor
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